retatrutide trial update october 2025 Lilly's triple agonist delivers up to 71.2 lbs of weight loss Retatrutide Delivers A1C Reduction, Weight

Contraindications: Who Should Avoid Retatrutide The contraindication list for Retatrutide largely mirrors what applies to the broader GLP-1/GIP receptor agonist class, with some nuances driven by the addition of glucagon receptor activity

Sodium Excretion: GLP-1 receptor agonism increases urinary sodium excretion

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD)

Most researchers report no noticeable potency issues at the 5-week mark, but conservative protocols suggest using the vial within 4 weeks and discarding any remainder